Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

FDA sets March 2027 review deadline for Aquestive’s oral anaphylaxis drug Anaphylm.

What the company is saying

Aquestive Therapeutics announces that the FDA has accepted its resubmission of the New Drug Application for Anaphylm, a sublingual epinephrine prodrug film, and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027. The company frames this as a major regulatory milestone, emphasizing that Anaphylm could become the first and only oral rescue medication for severe allergic reactions, including anaphylaxis, if approved. Daniel Barber, President and CEO, highlights the innovation and patient-centric design of Anaphylm, focusing on its portability and ease of use. The announcement stresses ongoing commercial preparations for a potential launch, and parallel regulatory progress in Canada, with a New Drug Submission to Health Canada targeted for Q4 2026. The tone is confident and forward-looking, with repeated references to unmet patient needs and the potential impact of Anaphylm. The company also references its broader epinephrine prodrug pipeline and proprietary PharmFilm technology, but provides no financial or commercial performance data.

What the data suggests

The FDA has formally acknowledged the NDA resubmission for Anaphylm as complete and classified it as a Class 2 response, setting a review deadline of March 16, 2027. Aquestive submitted the resubmission on September 16, 2026, following positive topline results from human factors and pharmacokinetic studies disclosed in August 2026, which were intended to address deficiencies raised in the FDA’s Complete Response Letter dated January 30, 2026. The Anaphylm trade name for AQST-109 has conditional FDA approval, pending final product approval. The company is also preparing a New Drug Submission to Health Canada, on track for Q4 2026. Product details are specific: Anaphylm is a polymer matrix-based epinephrine prodrug film, similar in size to a postage stamp, weighing less than an ounce, dissolving on contact, and packaged for portability and weather resistance. The AdrenaVerse platform includes over 20 epinephrine prodrugs, but no development timelines or clinical data for these are provided. No financial figures, sales data, or commercial agreements are disclosed. The only realised milestones are regulatory: NDA resubmission acceptance, PDUFA date assignment, and conditional trade name approval.

Analysis

The announcement is upbeat, highlighting the FDA's acceptance of the NDA resubmission and a set PDUFA goal date, which are concrete regulatory milestones. However, the majority of the positive claims—such as Anaphylm being the first and only oral rescue medication, its potential to address patient needs, and commercial launch preparations—are forward-looking and contingent on future FDA approval, which is not expected until March 2027 (over 17 months away). There is no disclosure of financial results, profitability, or commercial performance, and the company references advancing commercial preparations, implying capital outlay ahead of any revenue realization. The language around innovation, patient impact, and global regulatory progress inflates the narrative relative to the actual, measured progress, which is limited to regulatory process steps. The data supports that the NDA resubmission is complete and under review, but all commercial and market benefits remain speculative and long-dated.

Risk flags

• ●Regulatory approval risk remains high: The FDA’s acceptance of the NDA resubmission and assignment of a PDUFA date do not guarantee approval. The product must still clear all regulatory hurdles, and the FDA could request further information or additional studies, as previously occurred with the January 2026 Complete Response Letter.
• ●Execution risk on commercial readiness: The company is advancing commercial preparations ahead of approval, which may require capital outlay with no assurance of product launch or revenue if approval is delayed or denied. This exposes the company to potential financial strain if regulatory timelines slip.
• ●Pipeline and market adoption risk: While the company highlights a broad epinephrine prodrug pipeline and Anaphylm’s potential as a first-in-class oral rescue medication, there is no supporting data on market demand, payer acceptance, or competitive response. If Anaphylm fails to secure approval or adoption, pipeline value realization is uncertain.

Bottom line

Aquestive’s announcement marks a concrete regulatory milestone: the FDA has accepted its Anaphylm NDA resubmission and set a March 16, 2027, review deadline. This is a necessary step for potential U.S. market entry, but approval is not assured, and all commercial benefits remain at least 17 months away. The company’s narrative is optimistic, emphasizing innovation and patient need, but offers no new financial, sales, or partnership data to support near-term value. Investors should recognize that execution risks remain significant, especially given the history of FDA feedback and the capital required for commercial readiness. The most actionable fact is the PDUFA date; the next inflection point will be the FDA’s decision in March 2027. Until then, the story is defined by regulatory process, not commercial traction or financial performance.

Announcement summary

(NASDAQ:AQST) Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, and classified the resubmission as a Class 2 response. Aquestive submitted the resubmission to the Anaphylm NDA on September 16, 2026, following positive topline results from human factors and pharmacokinetic (PK) studies announced in August 2026, which were conducted to address items raised in the FDA’s January 30, 2026, Complete Response Letter. If approved, Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis. Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics, stated that the FDA’s acceptance of the resubmission and assignment of a Class 2 PDUFA date provides a clear path forward for Anaphylm. He emphasized the innovation of Anaphylm and its potential to address patient needs by providing a portable epinephrine treatment. Barber also noted that the company is advancing commercial preparations for a potential launch of Anaphylm, if approved. Aquestive continues to advance its ex-U.S. regulatory progress for Anaphylm and remains on track to complete its New Drug Submission to Health Canada in Q4 2026. Anaphylm is a polymer matrix-based epinephrine prodrug product candidate, similar in size to a postage stamp, weighing less than an ounce, and begins to dissolve on contact without the need for water or swallowing. The packaging is thinner and smaller than an average credit card, designed to withstand weather excursions such as exposure to rain and/or sunlight, and can be carried in a phone or wallet. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA, with final approval of the proprietary name conditioned on FDA approval of the product candidate. Aquestive is also advancing AQST-108 (epinephrine) topical gel for various potential dermatological conditions. The company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary technologies like PharmFilm®. The AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications.

Disagree with this article?